No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Abdominal Obesity Drugs market is a subset of the Anti-Obesity Drugs market, which is focused on the treatment of abdominal obesity. Abdominal obesity is a condition in which excess fat accumulates around the abdomen, leading to an increased risk of health complications. Abdominal obesity drugs are designed to reduce fat accumulation in the abdominal area, as well as reduce the risk of associated health complications. These drugs are typically prescribed in combination with lifestyle changes, such as diet and exercise. Commonly prescribed abdominal obesity drugs include orlistat, liraglutide, and phentermine.
Some of the major companies in the Abdominal Obesity Drugs market include Novo Nordisk, GlaxoSmithKline, Sanofi, Pfizer, and Takeda Pharmaceuticals. Show Less Read more
